Studienpraxis Urologie

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Prostate cancer10 trials
• Bladder cancer2 trials
• Kidney cancer2 trials

Phase

• Phase 36 trials
• Phase 23 trials
• Phase 2/32 trials
• Phase 11 trial
• Phase 1/21 trial

Status

• Completed5 trials
• Active, not recruiting4 trials
• Recruiting2 trials
• Terminated2 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company4 trials
• BioNTech SE1 trial
• Bristol-Myers Squibb1 trial
• F. Hoffmann-La Roche AG1 trial
• Hoffmann-La Roche1 trial
• and 6 more

Running trials

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

  Contact: Tilman Todenhöfer (principal investigator)

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

  Contact: Tilman Todenhöfer, Site 0080

• Recruiting

  PROCARE - PROstate Cancer Real World Evidence Registry

  NCT06835218· UroTrials Company (GmbH)· Source

  Contact: Tillmann Todenhöfer, Professor MD

• Active, not recruiting

  A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

  NCT05884398· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

  NCT04114825· Phase 2· RhoVac APS· Source

• Active, not recruiting

  A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

  NCT03706365· Phase 2/3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer2 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

  NCT05999968· Phase 1· Eli Lilly and Company· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  2023-505816-39-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

  NCT05458856· Phase 3· Ipsen· Source

• Terminated

  PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

  NCT04382898· Phase 1/2· BioNTech SE· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· pharmaand GmbH· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source